10-Q: Invivyd Narrows Loss, Advances COVID-19 Antibody

Invivyd, Inc. reported a significantly reduced net loss in the second quarter of 2025, driven by increased PEMGARDA sales, while advancing its next-generation COVID-19 antibody, VYD2311, towards potential BLA approval.

Summary

• Net loss for the six months ended June 30, 2025, significantly decreased to $30.9 million from $90.7 million in the prior year period.
• Product revenue, net, surged to $23.1 million for the six months ended June 30, 2025, up from $2.3 million in the same period last year, primarily due to PEMGARDA sales.
• Research and development expenses decreased by $41.3 million to $20.2 million for the six months ended June 30, 2025, compared to $61.5 million in the prior year.
• Selling, general and administrative expenses decreased by $2.7 million to $33.3 million for the six months ended June 30, 2025, from $36.0 million in the prior year.
• Cash and cash equivalents stood at $34.9 million as of June 30, 2025, down from $69.3 million at December 31, 2024.
• The company has an accumulated deficit of $932.9 million as of June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond one year without additional funding.

Sentiment

Score: 3

Explanation: While the company showed significant improvement in revenue and reduced net loss, the explicit 'substantial doubt about ability to continue as a going concern' and declining cash position are major red flags. Positive clinical data for VYD2311 and FDA alignment are strong, but the financial instability and Nasdaq compliance issues weigh heavily on the overall sentiment.

Positives

• Significant increase in product revenue to $23.1 million for the six months ended June 30, 2025, driven by PEMGARDA sales.
• Net loss substantially reduced to $30.9 million for the six months ended June 30, 2025, a $59.8 million improvement year-over-year.
• Positive full Phase 1/2 clinical data for VYD2311 (safety and pharmacokinetics) announced in June 2025.
• Alignment with FDA on a rapid pathway to potential Biologics License Application (BLA) approval for VYD2311, requiring a single Phase 2/3 trial.
• Formation of the SPEAR Study Group in July 2025 to explore VYD2311 for Long COVID and Post-Vaccination Syndrome (PVS).
• Continued neutralizing activity of PEMGARDA and VYD2311 against dominant SARS-CoV-2 variants (KP.3.1.1, LB.1, XEC, LP.8.1).

Negatives

• Substantial doubt about the ability to continue as a going concern beyond one year from the issuance date of the financial statements without additional funding.
• Significant accumulated deficit of $932.9 million as of June 30, 2025.
• Cash and cash equivalents decreased by $34.4 million to $34.9 million from December 31, 2024.
• Received a new Nasdaq non-compliance letter on April 21, 2025, for failing to meet the minimum $1.00 bid price requirement.
• Not yet satisfied the net product revenue milestone required to access proceeds from the $30 million Term Facility loan as of June 30, 2025.
• PEMGARDA's Emergency Use Authorization (EUA) is temporary and can be terminated or revoked.

Risks

• Inability to regain or maintain compliance with Nasdaq's continued listing standards, potentially leading to delisting.
• Failure to comply with covenants or other terms of the Loan Agreement, which could result in default and acceleration of debt.
• Inability to satisfy conditions for drawing down the $30 million Term Facility loans, including net product revenue milestones.
• Loan Agreement contains restrictions that limit business flexibility, such as incurring additional debt or making acquisitions.
• Need for significant cash to service indebtedness, with ability to generate cash dependent on factors beyond control.
• Uncertainty regarding the timing and progress of preclinical and clinical development activities for product candidates.
• Risks associated with obtaining and maintaining regulatory authorization or approval for product candidates.
• Uncertainty of market acceptance and commercialization success for products.
• Competition from other products in the biopharmaceutical industry.
• Dependence on key personnel and ability to attract and retain qualified employees.
• Reliance on third-party organizations for discovery, manufacturing, clinical, and commercial success.
• Potential for significant and changing government regulation and evolving treatment guidelines.
• Impact of business interruptions, including public health crises.

Future Outlook

The company expects to continue incurring significant expenses and losses as it commercializes PEMGARDA, advances VYD2311 through clinical development towards potential BLA approval, and expands its pipeline beyond SARS-CoV-2 to targets like RSV and measles. Future funding requirements are substantial, and the company anticipates needing additional capital through revenues, equity offerings, debt financings, or collaborations to support operations and growth.

Management Comments

• Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and commercialization of one or more of our product candidates, as they become authorized or approved.
• We may continue to incur significant expenses and recognize losses in the foreseeable future as we expand and progress our research and development activities, manufacturing activities and commercialization efforts.
• We will require additional funding through a combination of contribution from revenues, equity offerings, government or private-party grants, debt financings or other capital sources, such as collaborations with other companies, strategic alliances or licensing arrangements to support our continuing operations and pursue our growth strategy.
• If we are unable to secure additional funding when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy.
• Based on current operating plans and excluding any contribution from future revenues or external financing, we will not have sufficient cash and cash equivalents to fund our operating expenses and capital requirements beyond one year from the issuance date of the condensed consolidated financial statements in this Quarterly Report on Form 10-Q, and therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern.

Industry Context

The biopharmaceutical industry continues to focus on infectious diseases, with COVID-19 remaining a significant global health concern, particularly for immunocompromised individuals. Invivyd's strategy to develop next-generation monoclonal antibodies (mAbs) like VYD2311, with potential for broader application (e.g., Long COVID, PVS), aligns with the industry's need for evolving prevention and treatment options against viral evolution. The company's expansion into other respiratory viruses like RSV and measles indicates a broader strategic pivot beyond solely COVID-19, reflecting a trend among biopharma companies to diversify their infectious disease pipelines.

Comparison to Industry Standards

• The company's rapid pathway to potential BLA approval for VYD2311, based on FDA advice for a single Phase 2/3 trial, could be a significant acceleration compared to typical drug development timelines, potentially positioning it favorably against competitors in the COVID-19 mAb space.
• However, the substantial doubt about its ability to continue as a going concern and the need for additional financing are critical financial challenges that contrast with more established, cash-flow positive biopharmaceutical companies.
• The company's reliance on Emergency Use Authorization for PEMGARDA also highlights a less stable regulatory pathway compared to full FDA approvals held by some competitors.

Legal Proceedings

• As of June 30, 2025, the company was not a party to any material legal proceedings.

Related Party Transactions

• As of June 30, 2025, $0.5 million was due to Adimab under various agreements, included in accrued expenses.
• Expensed $0.4 million (Q2 2025) and $0.9 million (6M 2025) in royalties to Adimab as cost of product revenue under the Adimab Assignment Agreement.
• Recognized $0.6 million (Q2 2025) and $1.2 million (6M 2025) of research and development expense related to quarterly fees to Adimab under the Adimab Collaboration Agreement.
• Recognized $0.5 million (Q2 2025) and $1.0 million (6M 2025) of research and development expense related to annual fees to Adimab under the Adimab Platform Transfer Agreement.
• Recognized less than $0.1 million of R&D expense for services from Adimab under the Adimab DNA Sequencing Services Agreement.
• Tamsin Berry, a member of the company's board of directors, is a Limited Partner of Population Health Partners, L.P. (PHP), which holds warrants to purchase company common stock.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings; risk of delisting from Nasdaq; uncertainty regarding ability to continue as a going concern; potential for value creation if VYD2311 succeeds and financial stability is achieved.
• Employees: Continued employment contingent on company's ability to secure funding and continue operations; stock-based compensation plans are in place.
• Customers (Healthcare Providers/Patients): Continued availability of PEMGARDA for pre-exposure prophylaxis of COVID-19; potential for new treatment options with VYD2311 for COVID-19, Long COVID, and PVS.
• Suppliers/Creditors: WuXi Biologics has significant purchase obligations due in 2025 ($25.9 million for drug substance/product, $3.5 million for materials); Silicon Valley Bank is a lender with a secured term loan facility.

Next Steps

• Continue commercialization of PEMGARDA.
• Advance VYD2311 through clinical development, including a single Phase 2/3 randomized, double-blind, placebo-controlled trial for potential BLA submission.
• Launch multi-center translational clinical research on Long COVID and PVS through the SPEAR Study Group using VYD2311.
• Initiate and conduct clinical trials for other product candidates.
• Pursue regulatory authorization or approval for product candidates.
• Seek additional funding through revenues, equity offerings, government/private-party grants, debt financings, or collaborations.
• Monitor SARS-CoV-2 variants for antiviral activity.
• Assess pipeline expansion beyond SARS-CoV-2, including RSV and measles.
• Regain and maintain Nasdaq listing compliance.

Key Dates

Recommendation

While Invivyd demonstrated significant revenue growth from PEMGARDA sales and positive clinical progress with VYD2311, including FDA alignment for a rapid BLA pathway, the explicit 'substantial doubt about its ability to continue as a going concern' is a critical overhang. The company's cash position is declining, and it faces Nasdaq listing compliance issues. The potential for VYD2311 is promising, but the high financial risk and immediate need for additional capital make it a speculative investment. A 'hold' recommendation is appropriate for investors who are already exposed and wish to monitor the company's progress on securing funding and resolving its going concern issue, given the potential upside from VYD2311's development. New investors should exercise extreme caution due to the significant financial risks.

Keywords

Biopharmaceutical, Monoclonal Antibody, COVID-19, SARS-CoV-2, PEMGARDA, VYD2311, Emergency Use Authorization, Clinical Trials, Drug Development, Infectious Diseases, Going Concern, Nasdaq Listing, Biologics License Application, Long COVID, Post-Vaccination Syndrome